Join SCI Ventures at Society for Neuroscience 2024 in Chicago - whether you are a researcher, funder or partner! We will be on the lookout for innovations in neuro-regeneration and modulation in order to catalyze the next wave of companies in the space. We would love to talk to you! Our team will be there from 5-9th October. Message SCI Ventures or Roman Rothaermel on LinkedIn!
SCI Ventures
Venture Capital and Private Equity Principals
Global early-stage fund to catalyze the development of the next generation of treatments for paralysis
About us
SCI Ventures is the first global early-stage fund created to catalyze new cures for paralysis. Co-founded by leading global foundations and advised by world class neuroscientists, SCI Ventures invests in early-stage companies with an emphasis on technology to restore function while also backing the ultimate goal of a cure.
- Website
-
www.sciventures.com
External link for SCI Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Type
- Nonprofit
- Founded
- 2024
Employees at SCI Ventures
Updates
-
Thank you Matthieu Landon, economic advisor to President Macron, for having us at l'Elysée last week. Our MD Adrien Cohen and Matthieu Landon discussed how our evergreen specialist fund can foster innovation and lead to new therapies in spinal cord injuries and other neuro disorders. We look forward to investing and supporting more start-ups in France and Europe, and bring treatments from the lab to the real world!
-
Congratulations to our portfolio company ONWARD Medical for their listing on Euronext Paris this week. This will drive further liquidity in the stock to serve Onward's vision: to restore movement and bring new options to people living with paralysis! Congrats Dave Marver G. Courtine Jocelyne Bloch and the whole team!
🎉 ONWARD Medical poursuit sa lancée ! Hier avait lieu notre cotation officielle sur Euronext Paris, une étape importante dans notre mission de révolutionner le traitement des lésions de la moelle épinière et des troubles moteurs. Cela ouvre de nouvelles perspectives pour élargir notre réseau d’investisseurs et renforcer notre position sur le marché européen. C'est un levier qui nous permettra de continuer à innover et à développer des thérapies de pointe, tout en facilitant l'accès à nos actions pour nos partenaires et investisseurs. Grâce à cette avancée, nous restons concentrés sur notre vision : offrir des thérapies comme ARC-IM®, ARC-EX® et ARC-BCI™, porteuses d'espoir pour des milliers de personnes dans le monde. Un immense merci à tous ceux qui rendent cela possible ! Dave Marver, Jocelyne Bloch, G. Courtine, Alexandre Casteau, Vincent Delattre, Maria Vara, Sophie Stegen, Mathieu Caron, Nicolas Meunier, Charlène YVES, Gaultier de Tarade, Alain Baetens. #EmpoweringMovement #SCI #EuronextParis #Bourse *Tous les dispositifs et thérapies d’ONWARD Medical, y compris ARC-IM®, ARC-EX®, ARC-BCI™ et ARC Therapy™, seuls ou en combinaison avec une interface cerveau-machine (BCI), sont expérimentaux et ne sont pas encore disponibles à des fins commerciales.
-
"About 15 million people around the world have some form of spinal cord paralysis, a devastating situation for those who lack care and resources, as well as, to put it in more mercenary terms, a big cost to public health services and the wider economy. But Cohen thinks that harnessing investment resources and funnelling these into startups and specific scientific applied research can open the potential to resolve some of these problems" Thank you Tom Burroughes and Family Wealth Report for the conversation with our MD Adrien Cohen about the Venture Philanthropy model and the role of SCI Ventures to spark more innovation in neuro-regeneration. https://lnkd.in/e-JCfXFW
-
"Recently, I learnt about an exciting development. After many false dawns, it’s reignited real hope in me for advances in spinal medicine. For the first time some deeply committed, serious people, with deep pockets, are bringing the power of global venture capitalism to bear on the problem – a model which is already bearing fruit for other medical conditions. (...) The goal is to revolutionise spinal injury research through a huge potential market - the estimated 15.4m people worldwide with damaged spines, plus neurological conditions with common ground, strokes , MND, MS and Parkinson’s. (...) It rewards start-ups and gets promising ideas into a clinical setting. The same venture philanthropy model has already brought significant advances in cystic fibrosis and juvenile diabetes (...) It’s a profoundly human story about mending tragedy by harnessing the might of business – and it brings me enormous hope." Thank you @Melanie Reid @The Times for this powerful piece on SCI Ventures's mission and the people behind it - we all want to see more innovation in our field! cc Willie Watt @Ian Curtis https://lnkd.in/eTksxu_W
I’m finally feeling optimistic about a cure for spinal injuries
thetimes.com
-
It was a pleasure to take part in the Crick Innovation Challenge at the The Francis Crick Institute in London last week. Roman Rothaermel from our investment team served as a judge - congrats to the winning team, always exciting to see world-class scientists turning to entrepreneurship, especially in neuroscience!
-
"Raising money is difficult for companies in the uncertain world of medical research and development. But when foundations with strong scientific bona fides invest in an outfit, it’s an imprimatur that goes a long way toward giving other backers in philanthropy and the private investment sector the confidence and direction they need to pull the trigger when it comes to their own money." Thank you Inside Philanthropy for the great coverage on SCI Ventures'mission and approach as a catalyst for the field ! https://lnkd.in/efv_rmGx
Why Five Spinal Cord Injury Organizations Teamed Up to Launch a New Venture Philanthropy Fund | Inside Philanthropy
insidephilanthropy.com
-
It was a pleasure to attend the second SCI Investor Symposium in San Diego last week. In just one year, the event has grown from a few companies on stage to two full days with exciting companies lined up, both at the pre-clinical and clinical stage. Brain-computer interfaces, Cell & gene therapies, small molecule drugs, electrical stimulation... Our field is becoming more mature with significant commercial opportunities and treatments getting closer to market for our community. 👋 3 portfolio companies on stage Axonis Therapeutics Sania Therapeutics ONWARD Medical, alongside other exciting companies such as Neuralink Lineage Cell Therapeutics Inteligex NervGen Pharma Corp. ... Our Founding Managing Director Adrien Cohen introduced the pre-clinical session and gave an interview to BiotechTV - check it out!
𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: SCI Ventures is philanthropic but has been designed to invest in spinal cord injuries like a VC fund. Founding Managing Director Adrien Cohen describes how this $30M fund has been structured, what typical investments will look like, and how he hopes it will grow over time. Full video: https://lnkd.in/gQCZeH9u BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
It was a pleasure to connect with fellow VCs and social impact investors last week at the #SuperVenture conference in Berlin. Our Founding Managing Director Adrien Cohen spoke on the panel “Profit and Purpose: How impact can drive commercial success” about how SCI Ventures’ portfolio companies are supporting life-changing innovations in the field of paralysis while driving financial returns. Thank you to fellow panelists Douglas Sloan, Jon Coker, Alex Domin and Emma Steele for the interesting conversation! To learn more about SCI Ventures and our mission to catalyze an investment market aimed at reversing paralysis, visit us here: https://lnkd.in/e3jGYDKp
-
We are incredibly proud to have launched our first fund dedicated to catalyzing new treatments for spinal cord injury (SCI) with the backing of our co-founders: Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life - Spinal Cord Research Foundation and Promobilia Foundation. SCI Ventures invests in early-stage companies developing the next generation of treatments, with an emphasis on technology to restore function while also backing the ultimate goal of a cure. This includes a range of technologies, from medical devices to neurostimulation to gene & cell therapies. This is the first time that five leading foundations addressing spinal cord injury in the US, U.K. and EU have come together to support a novel investment vehicle. With their combined network and scientific expertise, we are uniquely positioned to activate the market and spark more innovation in the field. And since spinal cord injury is a natural starting point for many other neurological conditions, the technologies we back will yield impact beyond the SCI community. If you are working on exciting tech in neuro-regeneration, investing in neuroscience, or feel passionate about making a difference in the space - reach out!
SCI Ventures Launches Venture Philanthropy Fund to Accelerate Restorative Treatments for Spinal Cord Injury and a Cure for Paralysis
prnewswire.com